Csl Behring

This study tests whether a concentrated clotting medicine (fibrinogen) can better control heavy bleeding during surgery for pseudomyxoma peritonei, a rare tumor in the abdomen. About 90 adults will be randomly assigned to receive either the study drug or a standard blood product.…

This study tests an experimental drug called vamifeport in 84 adults with hereditary hemochromatosis, a genetic condition that causes too much iron buildup. The goal is to see if the drug can safely reduce iron stored in the liver, measured by MRI. Participants will take either v…

This study tests an inhaled drug called CSL787 in adults with non-cystic fibrosis bronchiectasis, a lung condition that causes chronic cough and infections. The goal is to see if the drug can delay or prevent sudden worsening of symptoms (flare-ups) compared to a placebo. About 4…

This study tests a single-dose gene therapy called CSL222 in 20 teenage boys (ages 12 to 17) with severe hemophilia B, a bleeding disorder. The treatment aims to help their bodies produce a missing clotting factor, potentially reducing or stopping the need for regular infusions. …

This study tests a one-time gene therapy called CSL222 for adults with severe or moderately severe hemophilia B who have antibodies that could block the treatment. The goal is to see if it reduces bleeding episodes. About 35 participants will receive the therapy and be monitored …

This program allows children aged 2 to 11 with hereditary angioedema (HAE) who completed a previous study to keep receiving garadacimab to prevent sudden, painful swelling attacks. Only children who responded well and had no serious side effects are eligible. The goal is to provi…

This study tests a new medicine (BE1116) against standard fresh frozen plasma to control bleeding in 200 adults during complex heart surgery with a heart-lung machine. The goal is to see if BE1116 corrects clotting problems more effectively. Participants are randomly assigned to …

This study tests two different doses of Privigen in children aged 2 to 17 with CIDP, a rare nerve condition that causes weakness. The goal is to see which dose better prevents relapses and controls symptoms. Participants may have used IVIG before or be new to treatment.

This study follows 200 people with hereditary angioedema (HAE) who are starting a new medicine called garadacimab. Researchers want to see how well it prevents swelling attacks in everyday life, how safe it is, and how it affects quality of life. Participants will be tracked for …

This study tests a drug called CSL300 in about 2,300 adults with end-stage kidney disease who are on dialysis and have signs of inflammation. The goal is to see if the drug can reduce the risk of heart attacks or heart-related death. Participants will receive either the drug or a…

This study tracks 500 people with hemophilia B who received HEMGENIX gene therapy to see how well it controls bleeding over time and if any safety issues arise. It also compares them to patients on standard factor IX shots. The goal is to understand if the treatment keeps working…

This study tests a new drug called anumigilimab in 63 adults with sickle cell disease to see if it is safe. Participants receive weekly injections for 64 weeks, starting with a low dose that increases to their personal maximum. The goal is to reduce painful crises that often requ…

This study tests an experimental drug called CSL889 in 70 adults and teens with sickle cell disease who are having a painful crisis. The drug is given through a vein and may help the crisis end faster. The main goals are to check safety and see how long it takes for pain to go aw…